FDA Grants Orphan Drug Designation For Galderma’s Trifarotene Molecule In The Treatment Of Congenital Ichthyosis
7/2/2014 11:28:10 AM
LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.
Help employers find you! Check out all the jobs and post your resume.
comments powered by